NDRG1 acts as an oncogene in triple-negative breast cancer and its loss sensitizes cells to mitochondrial iron chelation.

Jadhav SB, Vondrackova M, Potomova P, Sandoval-Acuña C, Smigova J, Klanicova K, Rosel D, Brabek J, Stursa J, Werner L, Truksa J

Open source

DOI: 10.3389/fphar.2024.1422369
Published: 2024
Container: Frontiers in pharmacology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2024.1422369,
  title = {NDRG1 acts as an oncogene in triple-negative breast cancer and its loss sensitizes cells to mitochondrial iron chelation.},
  author = {Jadhav SB and Vondrackova M and Potomova P and Sandoval-Acuña C and Smigova J and Klanicova K and Rosel D and Brabek J and Stursa J and Werner L and Truksa J},
  year = {2024},
  journal = {Frontiers in pharmacology},
  doi = {10.3389/fphar.2024.1422369},
  url = {https://doi.org/10.3389/fphar.2024.1422369}
}

RIS

TY  - JOUR
TI  - NDRG1 acts as an oncogene in triple-negative breast cancer and its loss sensitizes cells to mitochondrial iron chelation.
AU  - Jadhav SB
AU  - Vondrackova M
AU  - Potomova P
AU  - Sandoval-Acuña C
AU  - Smigova J
AU  - Klanicova K
AU  - Rosel D
AU  - Brabek J
AU  - Stursa J
AU  - Werner L
AU  - Truksa J
PY  - 2024
JO  - Frontiers in pharmacology
DO  - 10.3389/fphar.2024.1422369
UR  - https://doi.org/10.3389/fphar.2024.1422369
ER  -

APA

SB, J., M, V., P, P., C, S., J, S., K, K., D, R., J, B., J, S., L, W., & J, T. (2024). NDRG1 acts as an oncogene in triple-negative breast cancer and its loss sensitizes cells to mitochondrial iron chelation.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2024.1422369

Source records

pubmed · retrieved 2026-11-10T11:49:17.431Z